Partner with Immunitas Therapeutics to solve their R&D challenges
22-02-2023
X
Watch webinar
Enter your details below to access the audio and video recording of this event, and to receive updates about future virtual events.
If you’re already subscribed to IN-PART, please enter your details and you’ll be taken to the recordings.
By registering to attend you agree to receive emails about our virtual events. You can unsubscribe at any time through these emails. Information about how we store and process data in compliance with GDPR is outlined in our privacy policy.
In the third event of our latest Virtual Series, we spoke with Thomas Tan, Chief Scientific Officer at Immunitas Therapeutics. Dr Tan brings over 20 years of therapeutic research experience in both large and small biopharmaceutical settings across different disease areas, including infectious disease, autoimmunity, and oncology. In this partnering event with Immunitas Therapeutics, we heard about their R&D priorities and the research they’re looking for from academia.
What’s covered in this event?
- 00:00 – Introduction to IN-PART
- 03:35 – Introduction to Immunitas Therapeutics
- 08:40 – Immunitas strategy in immuno-oncology
- 15:11 – Example project: CD161
- 22:59 – Live Q&A
- 36:07 – Closing remarks
Format: Presentation followed by live Q&A (~40 minutes)
As part of our current Global Challenge uncovering next-generation immuno-oncology research, Immunitas Therapeutics have shared their interests through this webinar and in a one-page summary (company interests and priorities), with the view to identify new academic partners for collaboration and commercialisation partnerships.
About Immunitas Therapeutics: Immunitas Therapeutics is committed to discovering and developing novel, differentiated therapeutics for patients with cancer. Our discovery engine combines deep expertise in single-cell genomics with customized machine-learning approaches to elucidate immune cell populations that are key actors in immuno-oncology.
More Information:
In the first event of our Virtual Series, running alongside our latest Global Challenges campaign, we’ll be speaking with external innovation and R&D leads from our immuno-oncology campaign partners to hear about the roadblocks they face, and the priority research they’re looking for from academia to support their product and R&D pipelines.
Some of the topics covered will include:
- The top priorities and technical challenges for each company
- What research solutions companies are actively searching for from academia
- The companies’ preferred approaches to partnering with academic research and expertise
Who should attend?
- Technology transfer, research commercialisation + industry engagement teams
- Academic researchers
- Industry R&D and open/external innovation teams
Run in partnership with:
ASTP are Europe’s premier association of knowledge transfer professionals whose work aims to improve the quality of impact that public research has on the economy and society. Learn more.
PraxisAuril are a world-leading professional association for
knowledge exchange practitioners, whose network includes 5000+ KE professionals. Learn more.
Labiotech.eu provide the biotech community with current and relevant information about the life sciences industry. They hope that professionals in the industry will collaborate more effectively so they can develop better products that benefit our society. Learn more.
BIA: The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation. Learn more.
Copyrights reserved unless otherwise agreed – IN-PART Publishing Ltd., 2023: ‘Industry partnering event with Immunitas Therapeutics’
What is IN-PART?
IN-PART develops digital solutions, curated by in-house STEM experts, that simplify the initial connection between decision-makers in academia and industry. Our goal is to help drive impact from research by matching innovation and expertise on a level playing field globally.
Connect,a digital partnering platform for university-industry collaboration.
An online matchmaking platform used by 250+ universities and research institutes to connect with industry teams in 6,000+ companies to commercialise academic innovations and expertise that are available and seeking collaboration.
Discover, a bespoke scouting service for open innovation.
A bespoke scouting platform used by innovation-driven companies to profile the global landscape of academia across an active network of 2,600+ institutes, either through ‘Industry Calls for Opportunities’ or ‘Request for Proposal’ campaigns that find and confirm potential solutions to specific R&D challenges or requirements.